Program
ECC4703
A development code. Also written as “ECC4703 F0 formulation”, “ECC4703 F1 formulation” and “ECC4703 F2 formulation”.
Its studies are mostly in Non-alcoholic Fatty Liver Disease · Liver Diseases · Fatty Liver · Obesity, led by Eccogene.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eccogene | 54 open or running | phase 2since Dec 15, 2025 | Sep 13, 2022 | Dec 2026phase 1 · NCT07726368 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 13, 2022First study: early phase 1 study in Non-alcoholic Fatty Liver DiseaseFirst studyNCT05552274 · 75 enrolled · United States
- Dec 15, 2025Phase 2 study in Liver DiseasesPhase 2 reachedNCT07288138 · 160 planned · United States
- Dec 30, 2025Phase 1 study in Metabolic Dysfunction-Associated SteatohepatitisNCT07334080 · 72 planned · Australia
- Mar 5, 2026Phase 2 study in ObesityNCT07505303 · 151 enrolled · United States
- Jul 13, 2026Phase 1 study in Non-alcoholic Fatty Liver DiseaseNCT07726368 · 40 planned · Australia
Ahead
- Dec 2026Primary completion: phase 1 study in Non-alcoholic Fatty Liver DiseaseNCT07726368
- Apr 2027Primary completion: phase 1 study in Metabolic Dysfunction-Associated SteatohepatitisNCT07334080
- Sep 15, 2027Primary completion: phase 2 study in Liver DiseasesNCT07288138
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07726368Non-alcoholic Fatty Liver Disease · Australia | 1 | Recruiting | Dec 2026 | 40 |
| NCT07505303Obesity · United States | 2 | Active, not recruiting | Oct 15, 2026 | 151 |
| NCT07334080Metabolic Dysfunction-Associated Steatohepatitis · Australia | 1 | Recruiting | Apr 2027 | 72 |
| NCT07288138Liver Diseases · United States | 2 | Recruiting | Sep 15, 2027 | 160 |
| NCT05552274Non-alcoholic Fatty Liver Disease · United States | Early 1 | Completed | Oct 26, 2023 | 75 |
How it is read
Names in the registry
- “ECC4703”, 5 entries
- “ECC4703 F0 formulation”, 1 entry
- “ECC4703 F1 formulation”, 1 entry
- “ECC4703 F2 formulation”, 1 entry
- “ECC4703 F3 formulation”, 1 entry
Codes read as this program: ECC4703.
Conditions, from the studies’ own filings
- Non-alcoholic Fatty Liver Disease, 2 studies
- Liver Diseases, 1 study
- Fatty Liver, 1 study
- Obesity, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.